A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate Pembrolizumab Versus Placebo as Adjuvant Therapy Following Surgery and Radiation in Participants with High-risk Locally Advanced Cutaneous Squamous Cell Carcinoma(LA cSCC) (KEYNOTE-630).
S
Sara Grethlein, MD
Primary Investigator
Overview
The purpose of this study is to compare the recurrence-free survival (RFS), as assessed by the investigator and confirmed by biopsy, in individuals who receive pembrolizumab with individuals who receive placebo as adjuvant therapy.
Eligibility
You may be eligible for this study if you meet the following criteria:
-
Conditions:
Cutaneous squamous cell carcinoma
-
Age: Between 18 Years - 100 Years
-
Gender: All
Inclusion Criteria
In order to be eligible to take part in this trial, patients must meet the following criteria:
- Has histologically confirmed cutaneous squamous cell carcinoma (cSCC) as the primary site of malignancy (metastatic skin involvement from another primary cancer or from an unknown primary cancer is not permitted).
- Is disease free as assessed by the investigator with complete radiographic staging assessment less than or equal to 28 days from randomization.
For a full list of participation criteria, please visit clinicaltrials.gov.
Updated on
20 Apr 2024.
Study ID: 1903926878 (MK-3475-630)
